Congratulations to Dr. Timothy Bailey, President at Headlands Research – AMCR Institute, for his collaboration on a phase 3a study of CagriSema (cagrilintide + semaglutide). The study showed that once-weekly treatment led to significant weight loss and improved glycemic control in adults with type 2 diabetes.
Read the article in the New England Journal of Medicine.